Assessment of Actual Dose Adjustment in Patients Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%

被引：0
|
作者：
Luo, M. [1 ]
Iyer, R. [1 ]
Li-McLeod, J. [1 ]
机构：
[1] Baxter Healthcare Corp, Deerfield, IL 60015 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2012年 / 129卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2011.12.540
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：AB110 / AB110
页数：1
相关论文
共 50 条
  • [41] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
    Vollmer, Brandi
    Nair, Kavita
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2019, 92 (15)
  • [42] T-CD20 kinetics in patients switching to ocrelizumab therapy from fingolimod versus dimethylfumarate
    Signoriello, Elisabetta
    Romano, Giuseppe
    Abbondanza, Ciro
    D'agostino, Marina
    Maglio, Grazia
    Miele, Giuseppina
    Missione, Rosanna
    Coppola, Cinzia
    Bonavita, Simona
    Lus, Giacomo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 975 - 975
  • [43] POPULATION PHARMACOKINETIC (PK) MODELING AND SIMULATION OF VARIOUS DOSING INTERVALS AND DETERMINATION OF THE DOSE ADJUSTMENT FACTOR AFTER SC ADMINISTRATION OF IMMUNOGLOBULIN 20% (SCIG 20%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
    Dumas, Todd
    Wolfsegger, Martin
    Berry, N. Seth
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 205 - 206
  • [44] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    Gerth, William C.
    Betschel, Stephen D.
    Zbrozek, Arthur S.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2014, 10
  • [45] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10
  • [46] Health-Related Quality of Life of Patients with Primary Immunodeficiency Switching from Intravenous IgG to a New 20% Subcutaneous IgG
    Gonzalez Quevedo, Teresa
    Mannhardt-Laakmann, Wilma
    Bernatowska, Ewa
    Serban, Margit
    Jolles, Stephen
    de Gracia, Javier
    Grimbacher, Bodo
    Wang, Ed
    Borte, Michael
    CLINICAL IMMUNOLOGY, 2010, 135 : S87 - S87
  • [47] Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series
    Levine, Todd D.
    AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 : 965 - 970
  • [48] Neurologic Improvement after High-dose Intravenous Immunoglobulin Therapy in Patients with Paraneoplastic Cerebellar Degeneration Associated with Anti-Purkinje Cell Antibody
    Surasak Phuphanich
    Charles Brock
    Journal of Neuro-Oncology, 2007, 81 : 67 - 69
  • [49] Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature
    David Hefer
    Mohammed Jaloudi
    Annals of Hematology, 2004, 83 : 661 - 665
  • [50] Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature
    David Hefer
    Mohammed Jaloudi
    Annals of Hematology, 2005, 84 : 411 - 415
12345